Concepedia

Active Comparator Trials

Active Comparator Trials is a type of clinical trial design in pediatric research wherein the investigational intervention is compared against an existing, effective treatment rather than a placebo, thereby ensuring ethical rigor while evaluating relative efficacy and safety outcomes in the target pediatric population.

231

Publications

21.7K

Citations

2.1K

Authors

926

Institutions

Publications per year

2017–2026

107

Parents

Publications

231

The PREMIER study: A multicenter, randomized, double‐blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment

Ferdinand C. Breedveld, Michael H. Weisman, Arthur F. Kavanaugh et al. · Arthritis & Rheumatism · 2005 · 1.8K citations

, , +17

Trials to assess equivalence: the importance of rigorous methods: Fig 1

Byron Jones, Philip Jarvis, John A. Lewis et al. · BMJ · 1996 · 1K citations

, , +13

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial

Andrew Blauvelt, Kim Papp, C.E.M. Griffiths et al. · Journal of the American Academy of Dermatology · 2017 · 860 citations · Full text

, , +17

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial

Juan P. Frías, Michael A. Nauck, Joanna Van et al. · The Lancet · 2018 · 799 citations

, , +17

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial

Kristian Reich, April W. Armstrong, Peter Foley et al. · Journal of the American Academy of Dermatology · 2017 · 731 citations · Full text

, , +15

1–5 of 231

Authors

2.1K

  1. AB
    Andrew Blauvelt

    Oregon Medical Research Center, United States

    5 publications · 1.4K citations

    5

    h-index

  2. KR
    Kristian Reich

    Dermatologikum Hamburg, Germany

    5 publications · 1.7K citations

    5

    h-index

  3. BR
    B. Randazzo

    Janssen (United States), United States

    4 publications · 1.9K citations

    4

    h-index

  4. KB
    Kenneth B. Gordon

    Northwestern University, United States

    4 publications · 1.4K citations

    4

    h-index

  5. JR
    Julio Rosenstock

    Dallas Diabetes Research Center, United States

    4 publications · 739 citations

    4

    h-index

1–5 of 2.1K

Institutions

926

  1. Merck & Co., Inc., Rahway, NJ, USA (United States)

    Rahway, United States

    19 h-index

    100 publications

    7.6K citations

  2. Harvard University

    Cambridge, United States

    12 h-index

    25 publications

    3K citations

  3. University of Toronto

    Toronto, Canada

    11 h-index

    13 publications

    1.8K citations

  4. Pfizer (United States)

    New York, United States

    10 h-index

    29 publications

    858 citations

  5. Eli Lilly (United States)

    Indianapolis, United States

    9 h-index

    35 publications

    5.5K citations

  6. AbbVie (United States)

    North Chicago, United States

    8 h-index

    27 publications

    2.3K citations

  7. University of Washington

    Seattle, United States

    8 h-index

    8 publications

    2.6K citations

  8. Inserm

    Paris, France

    7 h-index

    8 publications

    528 citations

1–8 of 926

Venues

  1. Diabetes Obesity and Metabolism

    7 publications · 363 citations

    7

    h-index

  2. Current Medical Research and Opinion

    CMRO · 6 publications · 255 citations

    6

    h-index

  3. PubMed

    Repository · 6 publications · 243 citations

    6

    h-index

  4. JAMA Network Open

    5 publications · 171 citations

    5

    h-index

  5. Clinical Therapeutics

    5 publications · 505 citations

    5

    h-index

1–5